KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer
Hope S. Rugo, MD, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting.
Hope S. Rugo, MD, director of Breast Oncology Clinical Trials Investigation at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting, Rugo says.
There was a marked improvement in pathologic complete response (pCR) rates with the addition of pembrolizumab (Keytruda) to standard neoadjuvant chemotherapy in the KEYNOTE-522 trial. This trial was uniquely powered for event-free survival in 1200 patients with TNBC.
This trial showed a significant improvement in pCR with the addition of pembrolizumab in the range of 64% to 65%. This was really encouraging, says Rugo, as these rates are higher than what’s been observed with the addition of platinum.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
